JP2015517574A - がん治療のためのピリミジン化合物 - Google Patents
がん治療のためのピリミジン化合物 Download PDFInfo
- Publication number
- JP2015517574A JP2015517574A JP2015514115A JP2015514115A JP2015517574A JP 2015517574 A JP2015517574 A JP 2015517574A JP 2015514115 A JP2015514115 A JP 2015514115A JP 2015514115 A JP2015514115 A JP 2015514115A JP 2015517574 A JP2015517574 A JP 2015517574A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- group
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CVNJFZAKNJGUIX-ZKCHVHJHSA-N CSc(nc1)nc(N[C@H](CC2)CC[C@@H]2O)c1Br Chemical compound CSc(nc1)nc(N[C@H](CC2)CC[C@@H]2O)c1Br CVNJFZAKNJGUIX-ZKCHVHJHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261650000P | 2012-05-22 | 2012-05-22 | |
US61/650,000 | 2012-05-22 | ||
PCT/US2013/042033 WO2013177168A1 (en) | 2012-05-22 | 2013-05-21 | Pyrimidine compounds for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015517574A true JP2015517574A (ja) | 2015-06-22 |
JP2015517574A5 JP2015517574A5 (US07138402-20061121-C00069.png) | 2016-07-07 |
Family
ID=49624289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015514115A Pending JP2015517574A (ja) | 2012-05-22 | 2013-05-21 | がん治療のためのピリミジン化合物 |
Country Status (14)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019518796A (ja) * | 2016-06-27 | 2019-07-04 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ジアミノ−ピリミジン化合物ならびに該化合物の作製法および使用法 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
KR102063098B1 (ko) | 2011-10-03 | 2020-01-08 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 암 치료를 위한 피롤로피리미딘 화합물 |
WO2013177168A1 (en) | 2012-05-22 | 2013-11-28 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
WO2014058685A1 (en) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
CN104926801B (zh) * | 2014-03-22 | 2019-06-04 | 浙江大学 | 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
WO2015157122A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrazolopyrimidine compounds |
WO2017059280A1 (en) * | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
CN106749173A (zh) * | 2016-11-25 | 2017-05-31 | 吉林化工学院 | 一种嘧啶联吡啶类化合物的制备方法 |
US11053225B2 (en) | 2017-05-02 | 2021-07-06 | Korea Research Institute Of Chemical Technology | Pyrimidine derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and composition for preventing or treating Tyro 3 related disease comprising same as active ingredient |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
WO2022059996A1 (ko) * | 2020-09-15 | 2022-03-24 | 서울대학교 기술지주 주식회사 | 혈액 순환 미세체외소체 매개 암 치료용 조성물 |
KR102616469B1 (ko) * | 2020-09-15 | 2023-12-28 | 주식회사 유엔에스바이오 | 혈액 순환 미세체외소체 매개 암 치료용 조성물 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5516142B1 (US07138402-20061121-C00069.png) * | 1971-05-12 | 1980-04-30 | ||
WO2001083460A1 (fr) * | 2000-04-28 | 2001-11-08 | Tanabe Seiyaku Co., Ltd. | Composes cycliques |
JP2002533446A (ja) * | 1998-12-24 | 2002-10-08 | アストラゼネカ アクチボラグ | ピリミジン化合物 |
WO2004002964A1 (ja) * | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
JP2004502763A (ja) * | 2000-07-11 | 2004-01-29 | アストラゼネカ アクチボラグ | ピリミジン誘導体 |
WO2005009443A1 (en) * | 2003-06-24 | 2005-02-03 | Amgen Inc. | 2-amino-4-hydroxy-5-pyrimidinecarboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases |
JP2009510113A (ja) * | 2005-09-30 | 2009-03-12 | ブリストル−マイヤーズ スクイブ カンパニー | Metキナーゼインヒビター |
JP2009531394A (ja) * | 2006-03-30 | 2009-09-03 | テイボテク・フアーマシユーチカルズ・リミテツド | Hivを阻害する5−アミド置換されたピリミジン |
WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
WO2011065800A2 (ko) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
JP2011526299A (ja) * | 2008-06-27 | 2011-10-06 | アビラ セラピューティクス, インコーポレイテッド | ヘテロアリール化合物およびそれらの使用 |
WO2013157540A1 (ja) * | 2012-04-17 | 2013-10-24 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
JP2014525438A (ja) * | 2011-08-29 | 2014-09-29 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
US20080248046A1 (en) | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
EP1432714B1 (en) | 2001-10-02 | 2008-08-06 | Smithkline Beecham Corporation | Chemical compounds |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
WO2004106340A2 (en) | 2003-05-28 | 2004-12-09 | Università Degli Studi Di Siena | 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF |
US7129244B2 (en) | 2003-09-18 | 2006-10-31 | Conforma Therapeutics Corporation | Triazolopyrimidines and related analogs as HSP90-inhibitors |
JP5520433B2 (ja) | 2004-01-21 | 2014-06-11 | エモリー ユニバーシティー | 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用 |
JP2007520559A (ja) | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
AU2005214352B2 (en) | 2004-02-14 | 2009-11-12 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JPWO2005095382A1 (ja) * | 2004-03-30 | 2007-08-16 | 協和醗酵工業株式会社 | 抗腫瘍剤 |
EP2522670A1 (en) | 2004-04-07 | 2012-11-14 | Takeda Pharmaceutical Company Limited | Heterocyclic CRF receptor antagonists |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
KR20070057899A (ko) | 2004-09-30 | 2007-06-07 | 티보텍 파마슈티칼즈 리미티드 | Hiv를 억제하는 5-헤테로사이클릴피리미딘 |
WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
WO2007032445A1 (ja) * | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
EP1937258A2 (en) | 2005-09-23 | 2008-07-02 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
CN101321751A (zh) * | 2005-09-30 | 2008-12-10 | 布里斯托尔-迈尔斯·斯奎布公司 | Met激酶抑制剂 |
CA2624826A1 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
WO2007067730A2 (en) | 2005-12-08 | 2007-06-14 | Medarex, Inc. | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use |
US20080299113A1 (en) | 2005-12-19 | 2008-12-04 | Arnold Lee D | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents |
EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換2−アミノ縮合複素環式化合物 |
GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
WO2008111441A1 (ja) * | 2007-03-05 | 2008-09-18 | Kyowa Hakko Kirin Co., Ltd. | 医薬組成物 |
AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
DK2212297T3 (da) | 2007-10-12 | 2011-09-05 | Ingenium Pharmaceuticals Gmbh | Inhibitorer af proteinkinaser |
JP2011514881A (ja) | 2007-11-09 | 2011-05-12 | ザ ソルク インスティテュート フォー バイオロジカル スタディーズ | 免疫増強剤としてのtam受容体阻害剤の使用および免疫抑制剤としてのtam活性化剤の使用 |
US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8399206B2 (en) | 2008-07-10 | 2013-03-19 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
WO2010030781A2 (en) | 2008-09-10 | 2010-03-18 | Numed International, Inc. | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer |
WO2010038081A2 (en) * | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
GB0819105D0 (en) | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
US8513242B2 (en) | 2008-12-12 | 2013-08-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
WO2010085597A1 (en) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
TW201102391A (en) | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
CA2769822C (en) | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
CA2773661A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
EP2536410B1 (en) | 2010-02-18 | 2015-09-23 | Merck Sharp & Dohme Corp. | Substituted pyrimidine derivatives and their use in treating viral infections |
GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
AU2011330730B2 (en) | 2010-11-18 | 2016-02-18 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
MD20140023A2 (ro) | 2011-09-22 | 2014-06-30 | Pfizer Inc. | Derivaţi de pirolpirimidină şi purină |
KR102063098B1 (ko) | 2011-10-03 | 2020-01-08 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 암 치료를 위한 피롤로피리미딘 화합물 |
EP2817328A1 (en) | 2012-02-21 | 2014-12-31 | Institut National de la Santé et de la Recherche Médicale | Tam receptors as virus entry cofactors |
CN104662018B (zh) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
WO2013177168A1 (en) | 2012-05-22 | 2013-11-28 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
US20170202847A1 (en) | 2014-04-04 | 2017-07-20 | The University Of North Carolina At Chapel Hill | Methods for the treatment of tumors |
WO2015157122A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrazolopyrimidine compounds |
-
2013
- 2013-05-21 WO PCT/US2013/042033 patent/WO2013177168A1/en active Application Filing
- 2013-05-21 IN IN9610DEN2014 patent/IN2014DN09610A/en unknown
- 2013-05-21 MX MX2014013632A patent/MX2014013632A/es unknown
- 2013-05-21 AU AU2013266438A patent/AU2013266438B2/en not_active Expired - Fee Related
- 2013-05-21 US US14/384,789 patent/US9567326B2/en active Active
- 2013-05-21 KR KR1020147032028A patent/KR20150018789A/ko not_active Application Discontinuation
- 2013-05-21 JP JP2015514115A patent/JP2015517574A/ja active Pending
- 2013-05-21 RU RU2014145121A patent/RU2014145121A/ru not_active Application Discontinuation
- 2013-05-21 CN CN201380025291.3A patent/CN104302627A/zh active Pending
- 2013-05-21 BR BR112014028424A patent/BR112014028424A2/pt not_active Application Discontinuation
- 2013-05-21 CA CA2873878A patent/CA2873878A1/en not_active Abandoned
- 2013-05-21 EP EP13793925.2A patent/EP2852579A4/en not_active Withdrawn
-
2014
- 2014-11-16 IL IL235726A patent/IL235726A0/en unknown
-
2015
- 2015-07-20 HK HK15106878.7A patent/HK1206338A1/xx unknown
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5516142B1 (US07138402-20061121-C00069.png) * | 1971-05-12 | 1980-04-30 | ||
JP2002533446A (ja) * | 1998-12-24 | 2002-10-08 | アストラゼネカ アクチボラグ | ピリミジン化合物 |
WO2001083460A1 (fr) * | 2000-04-28 | 2001-11-08 | Tanabe Seiyaku Co., Ltd. | Composes cycliques |
JP2004502763A (ja) * | 2000-07-11 | 2004-01-29 | アストラゼネカ アクチボラグ | ピリミジン誘導体 |
WO2004002964A1 (ja) * | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
WO2005009443A1 (en) * | 2003-06-24 | 2005-02-03 | Amgen Inc. | 2-amino-4-hydroxy-5-pyrimidinecarboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases |
JP2009510113A (ja) * | 2005-09-30 | 2009-03-12 | ブリストル−マイヤーズ スクイブ カンパニー | Metキナーゼインヒビター |
JP2009531394A (ja) * | 2006-03-30 | 2009-09-03 | テイボテク・フアーマシユーチカルズ・リミテツド | Hivを阻害する5−アミド置換されたピリミジン |
JP2011526299A (ja) * | 2008-06-27 | 2011-10-06 | アビラ セラピューティクス, インコーポレイテッド | ヘテロアリール化合物およびそれらの使用 |
WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
WO2011065800A2 (ko) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
JP2014525438A (ja) * | 2011-08-29 | 2014-09-29 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
WO2013157540A1 (ja) * | 2012-04-17 | 2013-10-24 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019518796A (ja) * | 2016-06-27 | 2019-07-04 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ジアミノ−ピリミジン化合物ならびに該化合物の作製法および使用法 |
JP7065840B2 (ja) | 2016-06-27 | 2022-05-12 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4-ジアミノ-ピリミジン化合物ならびに該化合物の作製法および使用法 |
Also Published As
Publication number | Publication date |
---|---|
BR112014028424A2 (pt) | 2018-04-24 |
IN2014DN09610A (US07138402-20061121-C00069.png) | 2015-07-31 |
US9567326B2 (en) | 2017-02-14 |
CA2873878A1 (en) | 2013-11-28 |
MX2014013632A (es) | 2015-02-05 |
RU2014145121A (ru) | 2016-07-10 |
EP2852579A1 (en) | 2015-04-01 |
US20150038481A1 (en) | 2015-02-05 |
CN104302627A (zh) | 2015-01-21 |
AU2013266438B2 (en) | 2017-09-07 |
KR20150018789A (ko) | 2015-02-24 |
HK1206338A1 (en) | 2016-01-08 |
IL235726A0 (en) | 2015-02-01 |
EP2852579A4 (en) | 2015-12-30 |
AU2013266438A1 (en) | 2014-12-04 |
WO2013177168A1 (en) | 2013-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015517574A (ja) | がん治療のためのピリミジン化合物 | |
JP6316925B2 (ja) | 癌を治療するためのピロロピリミジン化合物 | |
US9771330B2 (en) | Pyrimidine compounds for the treatment of cancer | |
US9744172B2 (en) | Pyrazolopyrimidine compounds for the treatment of cancer | |
US9562047B2 (en) | Pyrazolopyrimidine compounds for the treatment of cancer | |
US20080319044A1 (en) | Compounds and Methods of Use Thereof | |
JP2008518923A (ja) | 化合物およびその使用方法 | |
WO2010014179A1 (en) | Photolabile caged transition metal complexes and methods of using the same | |
ES2253380T3 (es) | Bis-(n,n'-bis-(2-haloetil)amino)fosforamidatos como agentes antitumorales. | |
JP2022514685A (ja) | ペンタミジンの類似体及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160520 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160520 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170217 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170223 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170915 |